COLL
COLLEGIUM PHARMACEUTICAL, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.01
−0.78%Year over year
Reported trailing growth
- Revenue
- +14.3%
- EBITDA
- +36.5%
- EBIT
- +22.2%
- EPS
- +30.1%
- Free cash flow
- +62.7%
- Operating cash flow
- +62.1%
Forward estimates
Based on analyst estimates
- Revenue
- +6.5%
- EBITDA
- +46.1%
- EPS
- +354.0%
Three-year CAGR
- Revenue
- +18.9%
- EBITDA
- +32.3%
- EBIT
- +77.7%
- Net income
- +14.3%
- EPS
- +11.2%
- Free cash flow
- +38.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026